CSIMarket Company Name, Ticker, Competitors, else..


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 

Integrated Biopharma Inc

INBP's Fundamental analysis



Looking into Integrated Biopharma Inc growth rates, revenue grew by 15.69 % in II. Quarter 2024 from the same quarter a year ago. Ranking at No. 572

Major Pharmaceutical Preparations industry recorded growth of revenues by 11.85 %

Integrated Biopharma Inc realized net income compared to net loss a year ago in II. Quarter 2024

• More on INBP's Growth


Integrated Biopharma Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Integrated Biopharma Inc PEG ratio is at -0.03 Company is currently trading with Price to Cash flow multiple of 5.25 in trailing twelve-month period.
Company
10.36
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.17.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.


• More on INBP's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,041,480
 Net Income/Employee (TTM) $ 18,560
 Receivable Turnover (TTM) 11.57
 Tangible Book Value (Per Share $) 0.63

Integrated Biopharma Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Integrated Biopharma Inc PEG ratio is at -0.03 Company is currently trading with Price to Cash flow multiple of 5.25 in trailing twelve-month period.
Company
10.36
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.17.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.

Integrated Biopharma Inc Price to Book Ratio is at 0.46 lower than Industry Avg. of 79.76. and higher than S&P 500 Avg. of 0.01

• More on INBP's Valuation

•  Market Capitalization (Millions $) 9
•  Shares Outstanding (Millions) 31
•  Employees 50
•  Revenues (TTM) (Millions $) 52
•  Net Income (TTM) (Millions $) 1
•  Cash Flow (TTM) (Millions $) 2
•  Capital Exp. (TTM) (Millions $) -1
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,041,480
•  Net Income/Employee(TTM) $ 18,560
•  Receivable Turnover Ratio (TTM) 11.57
•  Tangible Book Value (Per Share $) 0.63

•  Market Capitalization (Millions $) 9
•  Shares Outstanding (Millions) 31
•  Employees 50
•  Revenues (TTM) (Millions $) 52
•  Net Income (TTM) (Millions $) 1
•  Cash Flow (TTM) (Millions $) 2
•  Capital Exp. (TTM) (Millions $) -1


    INBP's Profitability Comparisons
Integrated Biopharma Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in II. Quarter 2024 to 1.66 % from 3.66 % in I. Quarter.

Integrated Biopharma Inc net profit margin of 0.95 % is currently ranking no. 65 in Major Pharmaceutical Preparations industry, ranking no. 195 in Healthcare sector and number 2255 in S&P 500.


Profitability by Segment
Total 0.95 %



  Ratio
•   Capital Ratio (MRQ) 3.26
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.3
•  Asset Turnover Ratio (TTM) 2.03
•  Inventory Turnover Ratio (TTM) 4.21



Integrated Biopharma Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in II. Quarter 2024 to 1.66 % from 3.66 % in I. Quarter.

Integrated Biopharma Inc net profit margin of 0.95 % is currently ranking no. 65 in Major Pharmaceutical Preparations industry, ranking no. 195 in Healthcare sector and number 2255 in S&P 500.

• More on INBP's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com